Navigation Links
Angiotech and Symphony Medical Announce Licensing Agreement
Date:1/17/2008

ts or developments expressed or implied by such forward-looking statements. Such factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; technological changes that impact our existing products or our ability to develop and commercialize future products; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in drug discovery and clinical development processes; failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; dependence upon, and relationships with strategic alliance partners to develop and commercialize products and services based on our work; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; the requirement for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; the size of the market and the potential market for our products in specific disease areas, other factors referenced in our annual information form and other filings with the applicable Canadian securities regulatory authorities or the Securities and Exchange Commission; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to successfully complete preclini
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
2. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
3. Angiotech to participate in RBC 2007 Healthcare Conference
4. Angiotech to participate in Bank of America 2007 Credit Conference
5. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
8. Angiotech to participate in UBS Global Life Sciences Conference
9. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
10. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... have developed a unique nanoscale device that for ... The discovery could have major implications for creating ... and communication. , The research paper by University ... Mo Li and his graduate student Huan Li ... the October issue of Nature Nanotechnology . ...
(Date:9/22/2014)... , Sept. 22, 2014 US demand to ... for specialty biocides is forecast to rise 3.9 percent ... terms, demand is projected to increase 1.3 percent per ... A strong rebound in construction expenditures will support demand ... coatings markets, while growth in consumer spending and manufacturing ...
(Date:9/22/2014)... Research and Markets has announced ... Cellulose Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... industry including definitions, classifications, applications and industry chain structure. ...
(Date:9/22/2014)... September 22, 2014 FierceBiotech today announced ... held biotechnology companies of 2014. FierceBiotech editors John ... selecting this year’s winners. Those selected are identified ... in the industry. , "It's always a ... of Fierce 15 companies," said Carroll. "This year in ...
Breaking Biology Technology:Engineers show light can play seesaw at the nanoscale 2US Biocides Market 2US Biocides Market 3Global and Chinese Microcrystalline Cellulose Industry Report 2014 2FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2
... Aug. 23 AspenBio Pharma,Inc. (OTC Bulletin Board: APNB) ... drugs and diagnostics for animals and,humans, today announced its ... Markets Stock Exchange has been approved. The company ... the NASDAQ CM commencing with the open of trading ...
... ImmuneRegen,s Homspera(TM) Submitted to RFI, ,Therapeutic ... and B Threat Agents, SCOTTSDALE, Ariz., Aug. ... Inc. a wholly,owned subsidiary of IR BioSciences Holdings, ... has recently responded to a Request for,Information (RFI) ...
... Aug. 22 Biodel, Inc. (Nasdaq:,BIOD) today ... to its,Scientific Advisory Board (SAB). Dr. ... of Research,and Development at Kos Pharmaceuticals, where ... Kos was acquired by Abbott Laboratories. Dr.,Rosskamp,s ...
Cached Biology Technology:AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol 'APPY' 2AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol 'APPY' 3AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol 'APPY' 4ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information 2ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information 3Ralf Rosskamp, M.D. Joins Biodel's Scientific Advisory Board 2Ralf Rosskamp, M.D. Joins Biodel's Scientific Advisory Board 3
(Date:9/21/2014)... On the eve of United Nations General Assembly events ... of mothers, newborns and children, Grand Challenges Canada, funded ... in grants for 22 bold ideas to address this ... A program for Bangladeshi mothers working in garment ... thereby improving infant nutrition, reducing absenteeism due to child ...
(Date:9/21/2014)... strains of bacteria have emerged that resist even the ... forms of tuberculosis and staphylococcus, infect more than 2 ... the urgent need for new treatments, scientists have discovered ... decade. , MIT engineers have now turned a powerful ... that can disable any target gene, they have shown ...
(Date:9/19/2014)... from several Harvard University labs in collaboration with ... researchers with the intellectual raw materials needed to ... flexible materials. , With the advent of low-cost ... manufacturing technology, soft robotics is emerging as an ... rigid robot design, but working with pliable materials, ...
Breaking Biology News(10 mins):Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 2Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 3Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 4Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 5Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 6Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 7Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 8Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 9Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 10Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 11Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 12Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 13Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 14Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 15Battling superbugs 2Battling superbugs 3Battling superbugs 4Soft robotics 'toolkit' features everything a robot-maker needs 2
... one day be synthesised using biotechnology, following CSIRO,s discovery ... beetles with their potent predator defence system., CSIRO researchers, ... of the gene identification breakthrough and potential applications recently ... the first time, our team has been able to ...
... crocodiles and alligators are much prized by the fashion ... animals. Some are from endangered species and according to ... way to distinguish legitimate hides from poached skins is ... pigmented bumps that pepper crocodiles, bodies. Adding that the ...
... following 110,645 workers who helped clean up after the ... Soviet territory of Ukraine shows that the workers share ... may help scientists better define cancer risk associated with ... such as computed tomography scans and other sources. ...
Cached Biology News:Gene find turns soldier beetle defence into biotech opportunity 2Tactile croc jaws more sensitive than human fingertips 2Tactile croc jaws more sensitive than human fingertips 3Chernobyl cleanup workers had significantly increased risk of leukemia 2Chernobyl cleanup workers had significantly increased risk of leukemia 3
MBS 384 well satellite block unit with height adjusting heated lid, 384 well block holds 1 x 0.04 ml 384 well plate...
Wellpro 96 an automated liquid handling system for 96-well plates that quickly and accurately prepares large quantities of serial dilutions. The Wellpro also performs plate to plate transfers using ...
Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag...
...
Biology Products: